留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

《移植器官质量与安全指南(第6版)》解读—恶性肿瘤传播的风险

林俊 李诗新 杨洋

林俊, 李诗新, 杨洋. 《移植器官质量与安全指南(第6版)》解读—恶性肿瘤传播的风险[J]. 器官移植, 2020, 11(3): 400-404. doi: 10.3969/j.issn.1674-7445.2020.03.014
引用本文: 林俊, 李诗新, 杨洋. 《移植器官质量与安全指南(第6版)》解读—恶性肿瘤传播的风险[J]. 器官移植, 2020, 11(3): 400-404. doi: 10.3969/j.issn.1674-7445.2020.03.014
Lin Jun, Li Shixin, Yang Yang. Interpretation of Guide to the Quality and Safety of Organs for Transplantation(6th edition): risk of malignant tumor transmission[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 400-404. doi: 10.3969/j.issn.1674-7445.2020.03.014
Citation: Lin Jun, Li Shixin, Yang Yang. Interpretation of Guide to the Quality and Safety of Organs for Transplantation(6th edition): risk of malignant tumor transmission[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 400-404. doi: 10.3969/j.issn.1674-7445.2020.03.014

《移植器官质量与安全指南(第6版)》解读—恶性肿瘤传播的风险

doi: 10.3969/j.issn.1674-7445.2020.03.014
基金项目: 

北京市自然科学基金 7192043

北京市自然科学基金 7194250

北京市医院管理中心“青苗”计划 QML20190106

详细信息
    作者简介:

    李诗新,男,1995年,硕士,研究方向为肾脏移植,Email:lsx986841571@hotmail.com

    通讯作者:

    林俊,男,1973年,博士,主任医师,研究方向为肾脏移植,E-mail:13601355682@163.com

  • 中图分类号: R617, R73

Interpretation of Guide to the Quality and Safety of Organs for Transplantation(6th edition): risk of malignant tumor transmission

More Information
  • 摘要: 随着我国进入公民逝世后器官捐献时代,伴随潜在恶性肿瘤病史供者的器官捐献案例逐渐增多。欧盟编写的《移植器官质量与安全指南(第6版)》(《指南》)已于2019年出版中文译本。本文对《指南》第9章恶性肿瘤传播的风险进行了解读,以协助我国器官捐献协调员和移植团队筛查存在恶性肿瘤传播风险的供者,以减少供者来源性肿瘤疾病传播的风险。

     

  • 图  1  潜在器官移植供者的恶性肿瘤评估流程

    Figure  1.  Evaluation process of malignant tumor in potential organ transplant donors

  • [1] ISON MG, NALESNIK MA. An update on donor-derived disease transmission in organ transplantation[J]. Am J Transplant, 2011, 11(6):1123-1130. DOI: 10.1111/j.1600-6143.2011.03493.x.
    [2] DESAI R, COLLETT D, WATSON CJ, et al. Cancer transmission from organ donors-unavoidable but low risk[J]. Transplantation, 2012, 94(12):1200-1207. DOI: 10.1097/TP.0b013e318272df41.
    [3] NALESNIK MA, WOODLE ES, DIMAIO JM, et al. Donor‐transmitted malignancies in organ transplantation: assessment of clinical risk[J]. Am J Transplant, 2011, 11(6): 1140-1147. DOI: 10.1111/j.1600-6143.2011.03565.x.
    [4] GREEN M, COVINGTON S, TARANTO S, et al. Donor-derived transmission events in 2013: a report of the Organ Procurement Transplant Network Ad Hoc Disease Transmission Advisory Committee[J]. Transplantation, 2015, 99(2): 282-287. DOI: 10.1097/TP.0000000000000584.
    [5] SaBTO (The Advisory Committee on the Safety of Blood, Tissues and Organs). Transplantation of organs from deceased donors with cancer or a history of cancer[EB/OL]. (2014-04-01). https://www.odt.nhs.uk/transplantation/tools-policies-and-guidance/sabto/.
    [6] European Committee (Partial Agreement) on Organ Transplantation (CD-P-TO) EDQM[M].移植器官质量与安全指南(原书第6版).张雷, 译.北京: 科学出版社, 2019.
    [7] ECCHER A, CIMA L, CIANGHEROTTI A, et al. Rapid screening for malignancy in organ donors: 15-year experience with the Verona "Alert" protocol and review of the literature[J]. Clin Transplant, 2017, 31(9). DOI: 10.1111/ctr.13045.
    [8] KALIKI S, SHIELDS CL. Uveal melanoma: relatively rare but deadly cancer[J]. Eye (Lond), 2017, 31(2):241-257. DOI: 10.1038/eye.2016.275.
    [9] ECCHER A, LOMBARDINI L, GIROLAMI I, et al. How safe are organs from deceased donors with neoplasia? the results of the Italian Transplantation Network[J]. J Nephrol, 2019, 32(2): 323-330. DOI: 10.1007/s40620-018-00573-z.
    [10] VAN ERP AC, VAN DULLEMEN LFA, PLOEG RJ, et al. Systematic review on the treatment of deceased organ donors[J]. Transplant Rev (Orlando), 2018, 32(4):194-206. DOI: 10.1016/j.trre.2018.06.001.
    [11] MILLER AK, YOUNG JW, WILSON DJ, et al. Transmission of donor-derived breast carcinoma as a recurrent mass in a keratolimbal allograft[J]. Cornea, 2017, 36(6):736-739. DOI: 10.1097/ICO. 0000000000001185.
    [12] XIAO D, CRAIG JC, CHAPMAN JR, et al. Donor cancer transmission in kidney transplantation: a systematic review[J]. Am J Transplant, 2013, 13(10): 2645-2652. DOI: 10.1111/ajt.12430.
    [13] WILLIAMS T, ALJITAWI OS, MOUSSA R, et al. First case of donor transmitted non-leukemic promyelocytic sarcoma[J]. Leuk Lymphoma, 2012, 53(12): 2530-2534. DOI: 10.3109/10428194.2012.695360.
    [14] XIE L, ZHOU F. Development of lymphoma from the donor of haploidentical stem cell transplantation: a case report[J]. Mol Clin Oncol, 2017, 7(5): 851-854. DOI: 10.3892/mco.2017.1414.
    [15] DZIEWANOWSKI K, DROZD R, PARCZEWSKI, M et al. Multiorgan transplantation from a deceased donor with intravascular diffuse large B-cell lymphoma: transmission of the disease and results of treatment[J]. Clin Transplant, 2014, 28(10):1080-1083. DOI: 10.1111/ctr.12417.
    [16] CASSOL CA, HOD-DVORAI R, HUBBELL C, et al. Donor-derived philadelphia chromosome positive B-cell lymphoblastic leukemia presenting with renal allograft involvement in the first year post-transplant[J]. Am J Transplant, 2019, 19(3):956-957. DOI: 10.1111/ajt.15117.
    [17] TOFFALORI C, ZITO L, GAMBACORTA V, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation [J]. Nat Med, 2019, 25(4):603-611. DOI: 10.1038/s41591-019-0400-z.
    [18] SOSIN M, NASSIF SR, GIRLANDA R, et al. Isolated peritoneal donor-related plasmacytoma 3 years after liver transplantation: a case report[J]. Am J Transplant, 2014, 14(2):472-476. DOI: 10.1111/ajt.12555.
    [19] ARBER DA, ORAZI A, HASSERJIAN R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20):2391-2405. DOI: 10.1182/blood-2016-03-643544.
    [20] GRINFELD J, NANGALIA J, BAXTER EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms[J]. N Engl J Med, 2018, 379(15): 1416-1430. DOI: 10.1056/NEJMoa1716614.
    [21] BARBUI T, BAROSI G, BIRGEGARD G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet[J]. J Clin Oncol, 2011, 29(6):761-770. DOI: 10.1200/JCO.2010.31.8436.
    [22] WATSON C, ROBERTS R, WRIGHT K, et al. How safe is it to transplant organs from deceased donors with primary intracranial malignancy? an analysis of UK registry data[J]. Am J Transplant, 2010, 10(6): 1437-1444. DOI: 10.1111/j.1600-6143.2010.03130.x.
    [23] ZHAO P, STROHL A, GONZALEZ C, et al. Donor transmission of pineoblastoma in a two‐yr‐old male recipient of a multivisceral transplant: a case report[J]. Pediatr Transplant, 2012, 16(4): E110-E114. DOI: 10.1111/j.1399-3046.2010.01463.x.
    [24] CAVALIERE R, SCHIFF D. Donor transmission of primary brain tumors: a neurooncologic perspective[J]. Transpl Rev, 2004, 18(4): 204-213. DOI: 10.1016/j.trre.2004.09.003.
    [25] HYNES CF, RAMAKRISHNAN K, ALFARES FA, et al. Risk of tumor transmission after thoracic allograft transplantation from adult donors with central nervous system neoplasm—a UNOS database study[J]. Clin Transplant, 2017, 31(4). DOI: 10.1111/ctr.12919.
    [26] LOUIS DN, PERRY A, REIFENBERGER G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary[J]. Acta Neuropathol, 2016, 131(6):803-820. DOI: 10.1007/s00401-016-1545-1.
  • 加载中
图(1)
计量
  • 文章访问数:  416
  • HTML全文浏览量:  155
  • PDF下载量:  32
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-02-09
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2020-05-15

目录

    /

    返回文章
    返回